PRT-060318
Selleck Chemicals
SKU:E8145
Couldn't load pickup availability

PRT-060318 is an inhibitor of SYK used in studies of Immune Signaling. It is especially relevant in cancer, cell signaling, and immunology models, where defined compound exposure can be linked to cytokine-mediated signaling and inflammatory effector responses.
By inhibiting SYK, PRT-060318 can be used to examine cytokine-mediated signaling and inflammatory effector responses. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell signaling, and immunology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Target-focused assays involving SYK
- Pathway perturbation studies connected to Immune Signaling
- Concentration-response inhibition and target-dependence studies
- Biochemical kinase assays, phospho-signaling studies, and selectivity profiling
Overall, PRT-060318 is appropriate when a defined chemical perturbant is needed to connect SYK with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell signaling, and immunology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Targets:
- SYK
- Target Class:
- Kinase
- Pathways:
- Immune Signaling
- Research Area:
- Cancer • Cell Signaling • Immunology • Inflammation
- CAS No.:
- 1194961-19-7
- Molecular Weight:
- 340.42
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.